Sugi Predict

Sugi Predict / Compounds / SCHEMBL586732

SCHEMBL586732

SCHEMBL586732

CN1CCc2ccc(B3OC(C)(C)C(C)(C)O3)cc2C1

nearest known ligand 0.44

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ MAOA P21397 4/20 0.43
▸ MAOB P27338 4/20 0.43
▸ SLC6A4 P31645 1/20 0.41
▸ ROCK1 Q13464 1/20 0.39
▸ LPL P06858 5/20 0.39
▸ LIPG Q9Y5X9 5/20 0.39
▸ BACE1 P56817 1/20 0.39
▸ DRD1 P21728 2/20 0.38
▸ DRD5 P21918 2/20 0.38
▸ NOS3 P29474 1/20 0.37
▸ DRD2 P14416 1/20 0.36
▸ DRD4 P21917 1/20 0.36
▸ DRD3 P35462 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29623555 1.00 MAOA (0.43) MAOAMAOBSLC6A4ROCK1LPL
SCHEMBL586404 0.95 MAOA (0.46) MAOAMAOBSLC6A4ROCK1LPL
SCHEMBL29421599 0.95 MAOA (0.46) MAOAMAOBSLC6A4ROCK1LPL
SCHEMBL13144727 0.94 LPL (0.41) MAOAMAOBROCK1LPLLIPG
SCHEMBL29623587 0.94 LPL (0.41) MAOAMAOBROCK1LPLLIPG
SCHEMBL5001692 0.89 ROCK1 (0.44) ROCK1LPLLIPGBACE1
SCHEMBL31394828 0.89 ROCK1 (0.44) ROCK1LPLLIPGBACE1
SCHEMBL19650368 0.84 DRD1 (0.40) MAOAMAOBSLC6A4ROCK1LPL
SCHEMBL24753106 0.83 HRH3 (0.43) ROCK1LPLLIPGBACE1DRD1
SCHEMBL22816722 0.83 BACE1 (0.43) ROCK1LPLLIPGBACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163048-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2025-05-22 — — US disclosed
US-20240408169-A1 CYCLIN INHIBITORS CIRCLE PHARMA, INC. 2024-12-12 — — US disclosed
CN-116848113-A Bicyclic compounds as HPK1 inhibitors and application thereof 南京再明医药有限公司 2023-10-03 — — CN disclosed
WO-2023146990-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 — — WO disclosed
CN-116143779-A Compound of hematopoietic progenitor cell kinase 1 inhibitor, preparation method and application thereof 中国药科大学 2023-05-23 — — CN disclosed
CN-115433161-A Novel HPK1 inhibitor and preparation method and application thereof 轶诺(浙江)药业有限公司 2022-12-06 — — CN disclosed
CN-110713489-B Heteroaryl SYK inhibitors 勃林格殷格翰国际有限公司 2022-05-31 — — CN disclosed
CN-110183440-B Heteroaryl SYK inhibitors 勃林格殷格翰国际有限公司 2022-04-22 — — CN disclosed
US-10947243-B2 Heteroaryl SYK inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2021-03-16 — — US disclosed
CN-110713489-A Heteroaryl SYK inhibitors 勃林格殷格翰国际有限公司 2020-01-21 — — CN disclosed
US-7605266-B2 Azaindole inhibitors of Aurora kinases SMITHKLINE BEECHAM (US) 2009-10-20 — — US disclosed
US-7495102-B2 Azaindole inhibitors of aurora kinases SMITHKLINE BEECHAM CORPORATION (US) 2009-02-24 — — US disclosed
US-20080306120-A1 Treating a solid tumor cancer and a hematological cancer by administering N'-{4-[4-(2-{3-[(dimethylamino)methyl]phenyl}-1H-pyrrolo[2,3-b]pyridin-4-yl)-1-ethyl-1H-pyrazol-3-yl]phenyl}-N,N-dimethylurea; antitumor, -carcinogenic, proliferative agents; antiinflammatory agents; autoimmune diseases; fungicides GLAXOSMITHKLINE LLC 2008-12-11 — — US disclosed
EP-1962830-A2 AZAINDOLE INHIBITORS OF AURORA KINASES SmithKline Beecham Corporation (US) 2008-09-03 — — EP disclosed
US-7419988-B2 Azaindole inhibitors of aurora kinases SMITHKLINE BEECHAM CORP (US) 2008-09-02 — — US disclosed
US-20080081808-A1 AZAINDOLE INHIBITORS OF AURORA KINASES SMITHKLINE BEECHAM CORPORATION 2008-04-03 — — US disclosed
US-20080004308-A1 AZAINDOLE INHIBITORS OF AURORA KINASES GLAXOSMITHKLINE LLC 2008-01-03 — — US disclosed
US-7282588-B2 Azaindole inhibitors of aurora kinases SMITHKLINE BEECHAM (US) 2007-10-16 — — US disclosed
WO-2007076348-A2 AZAINDOLE INHIBITORS OF AURORA KINASES SMITHKLINE BEECHAM CORPORATION (US) 2007-07-05 — — WO disclosed
US-20070149561-A1 AZAINDOLE INHIBITORS OF AURORA KINASES GLAXOSMITHKLINE LLC 2007-06-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149561-A1 AZAINDOLE INHIBITORS OF AURORA KINASES AURKA, AURKC, AURKB MAOA 2765/4885MAOB 2779/4885SLC6A4 3646/4885
US-10947243-B2 Heteroaryl SYK inhibitors SYK, BTK, CD40 MAOA 1062/4885MAOB 1193/4885SLC6A4 4794/4885
US-20080081808-A1 AZAINDOLE INHIBITORS OF AURORA KINASES AURKA, AURKC, AURKB MAOA 2765/4885MAOB 2779/4885SLC6A4 3646/4885
US-20240408169-A1 CYCLIN INHIBITORS CCNI, CDK2, CDK1 MAOA 3377/4885MAOB 2734/4885SLC6A4 4819/4885
US-20250163048-A1 COMPOUNDS AND METHODS OF USE RB1, CYP1B1, REN MAOA 552/4885MAOB 135/4885SLC6A4 4225/4885
US-20080004308-A1 AZAINDOLE INHIBITORS OF AURORA KINASES AURKA, AURKC, AURKB MAOA 2765/4885MAOB 2779/4885SLC6A4 3646/4885
US-20080306120-A1 Treating a solid tumor cancer and a hematological cancer by administering N'-{4-[4-(2-{3-[(dimethylamino)methyl]phenyl}-1H-pyrrolo[2,3-b]pyridin-4-yl)-1-ethyl-1H-pyrazol-3-yl]phenyl}-N,N-dimethylurea; antitumor, -carcinogenic, proliferative agents; antiinflammatory agents; autoimmune diseases; fungicides AURKA, AURKC, AURKB MAOA 3932/4885MAOB 4015/4885SLC6A4 4139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.